Meritage Homes
MTH
KB Home
KBH
D.R. Horton
DHI
4
Adobe
ADBE
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 1.410
- +0.100+7.63%
Close Apr 30 16:00 ET
375.24MMarket Cap-1.64P/E (TTM)
1.410High1.270Low1.73MVolume1.280Open1.310Pre Close2.36MTurnover1.26%Turnover RatioLossP/E (Static)266.13MShares5.00052wk High0.88P/B194.71MFloat Cap1.10552wk Low--Dividend TTM138.09MShs Float53.240Historical High--Div YieldTTM10.69%Amplitude1.105Historical Low1.361Avg Price1Lot Size
About Autolus Therapeutics Company
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Company Profile
SymbolAUTL
Company NameAutolus Therapeutics
Listing DateJun 22, 2018
Issue Price17.00
Founded2018
CEODr. Christian Itin, PhD.
MarketNASDAQ
Employees647
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressThe Mediaworks,191 Wood Lane,White City
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW12 7FP
Phone44-20-3829-6230
Websitehttp://www.autolus.com
Company Executives
- Name
- Position
- Salary
- Dr. Christian Itin, PhD.
- Chief Executive Officer and Director
- 1.93M
- Miranda Neville
- Senior Vice President and Chief Project Officer
- --
- Martin Pule, M.B.B.S.
- Senior Vice President and Chief Scientific Officer
- --
- David Brochu
- Senior Vice President and Chief Technical Officer
- --
- Christopher Vann
- Senior Vice President and Chief Operating Officer
- --
- Brent Rice
- Senior Vice President and Chief Commercial Officer
- --
- Alexander Swan
- Senior Vice President and Chief Human Resources Officer
- --
- Dr. Matthias Will, M.D.
- Senior Vice President and Chief Development Officer
- --
- Dr. Christopher Willia PhD
- Senior Vice President and Chief Business Development Officer
- --
- Robert F. Dolski
- Senior Vice President, Principal Accounting Officer and Chief Financial Officer
- --
- Alex Driggs
- Senior Vice President, Legal Affairs and General Counsel
- --
- Andrew Mercieca
- Vice President, Finance
- --
- Michael W. Bonney
- Chairman of the Board
- 389.12K
- Linda C. Bain
- Independent Director
- 196.20K
- Cynthia M. Butitta
- Independent Director
- 190.82K
- William D. Young, PhD
- Independent Director
- 196.66K
- Robert W. Azelby
- Independent Director
- 371.16K
- John E. Berriman
- Independent Director
- 189.32K
- Dr. Robert Iannone, M.D.
- Independent Director
- 193.94K
- Dr. Ravi Madduri Rao, M.D.
- Independent Director
- 302.73K
- Dr. Martin Patrick Murphy, PhD
- Independent Director
- 184.33K
- Dr. Joseph Anderson, PhD.
- Independent Director
- 189.70K
- Dr. Elisabeth Leiderman, M.D.
- Independent Director
- 326.45K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025